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To reduce the burden of heart attack  and stroke in the United States,  the U.S. Department of Health and Human 
Services launched Million Hearts®. The goal of 
this initiative is to prevent 1 million heart  
attacks and strokes by 2017 by implementing 
proven and effective interventions in clinical 
settings and communities. Million Hearts®  
brings together communities, health systems,  
nonprofit organizations, federal agencies,  
and private-sector partners from across the 
country to fight heart disease and stroke.
Smoking is one of the leading causes of heart 
disease and stroke, accounting for 32% of 
coronary heart disease deaths.¹ Although the 
proportion of U.S. adults who smoke cigarettes 
has steadily decreased over the past 50 years,  
to approximately 17% in 2014, large disparities  
in smoking rates remain across racial/ethnic 
groups, socioeconomic statuses, and geographic 
areas and among people with mental health  
and substance use disorders.1,2,3 
About 36.5 million U.S. adults continue to  
smoke cigarettes, resulting in about 480,000 
smoking-related deaths each year in the United 
States.1,2 At least 70% of cigarette smokers see  
a clinician annually,⁴ and most want to quit.4,5 
However, fewer than 25% of tobacco users 
leave a health care visit with evidence-based 
counseling and medication.⁶ 
The purpose of this document is to provide 
evidence-based, tested tobacco use identification 
and intervention strategies for busy clinicians. 
These strategies were gathered from the 
published scientific literature, including the  
U.S. Public Health Service–sponsored Clinical 
Practice Guideline Treating Tobacco Use and 
Dependence: 2008 Update.⁴
The strategies are organized into two categories 
of actions:
ZZ Improve delivery system design (Table 1). 
ZZ Increase evidence-based brief 
interventions for patients who use tobacco 
(Table 2 and Table 3). 
This document concludes with additional 
resources and references where more detailed 
information can be found. 
Strategies for Tobacco Cessation 
Tobacco dependence is a chronic health 
condition that often requires multiple,  
discrete interventions by a clinician, team of 
clinicians, or health systems. The 5 A’s brief 
intervention for treating tobacco dependence 
(Ask, Advise, Assess, Assist, and Arrange 
follow-up) is a useful way to understand and 
address tobacco dependence treatment and 
organize the clinical team to implement an 
intervention. Although a single clinician can 
provide all 5 A’s, it is often more time- and  
cost-effective to have the 5 A’s divided up  
among teams of clinicians and staff. 
Clinician treatment extenders such as tobacco 
cessation quitlines, Web-based cessation 
interventions, and in-clinic and local cessation 
programs, can and should be incorporated into 
the 5 A’s approach. These treatment extenders 
support and streamline clinical interventions.
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Table 1. Actions to Improve Tobacco Cessation Delivery System Design⁴
Implement a standardized tobacco use identification and intervention system and workflow,  
including asking about or verifying every patient’s tobacco use status. See Table 2 for an evidence-based brief 
intervention model.
Identify and engage tobacco cessation champions within your practice or organization.
Proactively track and contact patients who use tobacco, using an electronic health record (EHR)–generated list, 
patient registry, or other data source.
Proactively provide ongoing support for patients who use tobacco through telephone, EHRs, office visits, or other 
means, as you do for patients with other chronic conditions.
Implement systems to alert clinicians or physicians about patients identified as tobacco users. Build clinical 
decision support into EHRs, such as best practice advisories, algorithms, alerts, reminders, clinical guidelines, counseling, 
templates or language, tobacco cessation medication, and referral forms.
Provide feedback to individual clinicians and clinic sites on their rate of tobacco use identification and 
intervention. Provide recognition for high performance. Invite outstanding performers to share their strategies for 
tobacco use identification and intervention with their peers.
Remind patients and staff that all tobacco cessation clinical services are offered at no charge to the patient. 
Use both counseling and medication (unless contraindicated), as currently recommended by the U.S. Preventive Services 
Task Force and the U.S. Public Health Service. In May 2014, the U.S. Departments of Health and Human Services,  
Labor, and Treasury issued a guidance on what the Affordable Care Act preventive services requirement means for 
tobacco cessation coverage. The guidance recommends covering at least two quit attempts per year, with each quit 
attempt including four tobacco cessation counseling sessions of at least 10 minutes each and a 90-day course of one  
or more of the seven Food and Drug Administration (FDA)–approved cessation medications. The guidance recommends 
covering both counseling and medications with no cost-sharing or prior authorization. 
Encourage clinicians to take continuing education on evidence-based tobacco dependence treatment.  
The University of Wisconsin provides a free, online continuing medical education course7 (http://bit.ly/2siWnIR) based on 
the 2008 Public Health Service Clinical Practice Guideline Treating Tobacco Use and Dependence.⁴
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Table 2. The 5 A’s Tobacco Cessation Brief Intervention Model⁴
Ask all patients about tobacco use.* Identify or verify and document tobacco use status of every patient at every visit.
*“The USPSTF concludes that the current evidence is insufficient to recommend electronic 
nicotine delivery systems (ENDS) for tobacco cessation in adults, including pregnant women. 
The USPSTF recommends that clinicians direct patients who smoke tobacco to other cessation 
interventions with established effectiveness and safety (previously stated).”8 No evidence-based 
cessation interventions have been identified specifically for exclusive ENDS users.
Advise all tobacco users to quit. In a clear, strong, and personalized manner, urge every tobacco user to quit. 
“The most important thing you can do to improve your health is to quit 
smoking, and I can help you.” Advice should be:
 
 
 
• Clear. “It is important that you quit smoking/using chewing tobacco now,  
and I can help you. Occasional or light smoking is still dangerous.”
• Strong. “As your clinician, I need you to know that quitting smoking is the 
most important thing you can do to protect your health now and in the future. 
The clinic staff and I will help you.”
• Personalized. Tie tobacco use to current symptoms and health concerns, 
social and economic costs, and/or the impact of tobacco use on children and 
others in the household. “Continuing to smoke makes your asthma worse,  
and quitting may dramatically improve your health. Quitting smoking may 
reduce the number of ear infections your child has.”
Assess willingness to quit now. For each tobacco user, ask whether she or he is willing to make a quit 
attempt now. “Are you willing to quit within the next month if I provide 
help for you?”
For former tobacco users, ask how recently she or he quit and whether they 
are experiencing any challenges to remaining abstinent.
Assist the tobacco user with a quit plan. For the patient willing to make a quit attempt, assist with creating a quit plan, 
offer medication, and provide or refer the patient for counseling to help them 
quit. Evidence strongly suggests that the combination of medication and 
counseling dramatically improves the chances of quitting successfully. 
The action steps below may be completed by an individual clinician or by 
a team of health care providers. Providing referrals does not take the place 
of your clinical intervention; rather, referrals are an extension of the tobacco 
cessation treatment you provide.
 • Help the patient create a quit plan. As part of a patient’s preparation  
for quitting, encourage them to take the following steps (STAR):
Set a quit date, ideally within 2 to 4 weeks.
Tell your family, friends, and coworkers about quitting and ask for  
their support.
Anticipate challenges, particularly during the critical first few weeks. 
Challenges include nicotine withdrawal symptoms.
Remove tobacco products from your environment. Prior to quitting, avoid 
smoking in places where you spend a lot of time (e.g., work, home, car).  
Make your home smoke-free.
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Table 2. The 5 A’s Tobacco Cessation Brief Intervention Model⁴ (continued)
Assist the tobacco user with a quit plan 
(continued).
 • Recommend FDA-approved medication, except where contraindicated 
or in specific populations for which there is insufficient evidence of 
effectiveness (e.g., pregnant women, adolescents, people who smoke five 
or fewer cigarettes per day, and smokeless tobacco users). Explain how 
medication reduces withdrawal symptoms and makes it more likely that 
patients will succeed in quitting. Consider use of combination therapy to 
provide patient with both a long-acting and a short-acting (craving relief ) 
medication. FDA-approved medications include the following:
Short-acting: Nicotine gum, nicotine lozenge, nicotine inhaler,  
nicotine nasal spray
Long-acting: Nicotine patch, bupropion SR (non-nicotine pill and 
nicotine antagonist), varenicline (non-nicotine pill, nicotine antagonist,  
and nicotine agonist), patch and bupropion SR in combination
 • Provide practical counseling, including problem-solving or skills training:
Make abstinence the goal. Striving for abstinence is essential.  
“Not even a single puff after the quit date.”
Review past quit experience. Help the patient identify what helped and 
what did not work in previous quit attempts. Build on past successes.
Anticipate challenges or triggers for the upcoming quit attempt. 
Discuss challenges or triggers and how the patient can overcome them  
(e.g., avoiding triggers, altering routines). Stress self-efficacy.
Avoid alcohol. Because alcohol is associated with relapse, encourage 
the patient to consider limiting alcohol consumption or abstaining from 
alcohol while quitting, at least for the first 30 days. 
Engage other smokers in the household. Quitting is more difficult 
when there is another smoker in the household. Patients should 
encourage housemates to quit with them or at least to not smoke in 
their presence and in shared homes and vehicles.
 • Provide referral to supplemental counseling and other resources, 
including information on or referral to a tobacco cessation quitline,  
such as the U.S. 800-QUIT-NOW helpline.
Sources: In-house clinic or system tobacco cessation services;  
state tobacco quitlines (800-QUIT-NOW); local, state, or tribal tobacco 
cessation resources; the National Cancer Institute cessation website  
http://www.smokefree.gov; and the Centers for Disease Control  
and Prevention (CDC) Tips From Former Smokers website,  
http://www.cdc.gov/tobacco/campaign/tips
Locations: Tobacco cessation counseling resources or referrals 
integrated into the EHR or available in exam rooms
For the recent quitter and any patient experiencing challenges with 
quitting, provide relapse prevention and support. Initiate a brief discussion 
with the patient focused on the following:⁴
 • Successes the patient has had in quitting
 • Issues encountered (e.g., stress, other smokers)
 • Correct use of any medication prescribed
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Table 2. The 5 A’s Tobacco Cessation Brief Intervention Model⁴ (continued)
Assist the tobacco user with a quit plan 
(continued).
For patients unwilling to quit at this time, provide brief motivational 
messages to increase the likelihood of a future quit attempt, such as, “I feel 
so strongly about tobacco use and its effect on your health that I will ask 
you about it when I see you next.” Use “Enhancing Patient Motivation to 
Quit Tobacco Use—The 5R Model.”⁴
 • Relevance. Encourage the patient to indicate why quitting is personally 
relevant, being as specific as possible. Motivational information has the 
greatest impact if it is relevant to a patient’s disease status or risk,  
health concerns, family or social situation (e.g., having children in the 
home), age, gender, and other important patient characteristics  
(e.g., prior quitting experience, personal barriers to cessation). 
 • Risks. Ask the patient to identify potential negative consequences of 
smoking. Highlight those consequences that seem most relevant to 
the patient. Examples of consequences include shortness of breath, 
exacerbation of asthma, increased risk of respiratory infections, harm to 
pregnancy, impotence, infertility, heart attacks, strokes, lung and other 
cancers, chronic obstructive pulmonary disease, osteoporosis, long-term 
disability, and the need for extended care. Risks to the patient’s family 
members from secondhand tobacco smoke include increased risk of heart 
disease, stroke, and lung cancer in spouses or partners, and increased risk 
of sudden infant death syndrome, asthma attacks, ear infections,  
and respiratory infections in children. 
 • Rewards. Ask the patient to identify potential benefits of stopping 
tobacco use, and highlight those that seem most relevant.  
Examples of rewards include improved health; improved sense of taste 
and smell; healthier babies/children; setting a good example for children;  
saving money; better-smelling home, car, clothing, and breath;  
improved self-esteem; and improved appearance. 
 • Roadblocks. Ask the patient to identify barriers to quitting, and provide 
treatments (problem-solving counseling, medication) that address these 
barriers. Typical barriers include withdrawal symptoms, fear of failure,  
fear of weight gain, lack of support, depression, being around other 
tobacco users, and limited knowledge of effective treatment options. 
 • Repetition. Remind the patient that most people make repeated quit 
attempts before they are successful.
Arrange follow-up with the patient. All patients receiving the brief tobacco cessation intervention should 
receive follow-up to monitor challenges and medication adherence. 
Follow-up can take place at a clinic, via EHR, or via phone.
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Table 3. FDA-Approved Tobacco Cessation Medications*4, 9,10
Medication and 
description 
Cautions/
Warnings Side Effects Dosage Use Availability
Nicotine Gum  
(2 mg or 4 mg)
Short-acting rescue 
for cravings 
 
 
• Use caution with 
dentures
• Do not eat  
or drink 15 
minutes before 
use or during use
 
 
• Mouth soreness
• Stomach ache
 
 
 
 
 
• One piece every 
1–2 hours
• 6–15 pieces  
per day
• If smoking more 
than 30 minutes 
after waking: 2 mg
• If smoking 30 
minutes after 
waking: 4 mg
• Waking: 4 mg
 
 
• After quitting:  
Up to 12 weeks
• Optional  
before quitting: 
Up to 6 months 
prior to quit date 
with smoking 
reduction
OTC only:
 
 
• Generic
• Nicorette
Nicotine Inhaler
Package insert: 
http://on.pfizer.com/ 
277NZv1
Short-acting rescue 
for cravings 
May irritate mouth 
or throat at first 
(improves with use)
Local irritation of 
mouth and throat
 
 
 
• 6–16 cartridges  
per day
• Inhale 80 times 
per cartridge
• Can save partial 
cartridge for  
next dose
 
 
• After quitting: 
Up to 6 months, 
tapering at end
• Optional  
before quitting: 
Up to 6 months 
prior to quit date 
with smoking 
reduction
Prescription only: 
Nicotrol inhaler
Nicotine Lozenge 
(2 mg or 4 mg)
Short-acting rescue 
for cravings
 
 
 
• Do not eat  
or drink 15 
minutes before 
use or during use
• Take one lozenge 
at a time
• Use no more than 
20 in 24 hours
 
 
 
• Hiccups
• Cough
• Heartburn
 
 
 
 
 
• If smoking more 
than 30 minutes 
after waking: 2 mg
• If smoking within 
30 minutes of 
waking: 4 mg
• Weeks 1–6: 1 
every 1–2 hours
• Weeks 7–9: 1 
every 2–4 hours
• Weeks 10–12: 1 
every 4–8 hours
3–6 months OTC only:
 
 
 
• Generic
• Commit
• Nicorette 
mini-lozenge
Nicotine Nasal 
Spray
Package insert: 
http://on.pfizer.com/ 
1TzNm34
Short-acting rescue 
for cravings 
 
 
 
 
• Not for patients 
with asthma
• May irritate nose 
(improves over 
time)
• May cause 
dependence
• Do not inhale
Nasal irritation  
 
 
• Dose = 1 squirt 
per nostril
• 1–2 doses  
per hour
• 8–40 doses  
per day
3–6 months, 
tapering at end
Prescription only: 
Nicotrol NS
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Table 3. FDA-Approved Tobacco Cessation Medications*4, 9,10 (continued)
Medication and 
description 
Cautions/
Warnings Side Effects Dosage Use Availability
Nicotine Patch
(7 mg, 14 mg,  
or 21 mg)
Long-acting 
steady-state 
replacement 
Do not use if 
you have severe 
eczema or 
psoriasis.
 
 
• Local skin 
reaction
• Insomnia
 
 
 
 
• 1 patch per day
• If smoking 10 or 
more cigarettes  
per day, start at  
21 mg for 4 
weeks
• 14 mg for 2–4 
weeks
• 7 mg for 2–4 
weeks
 
 
• After quitting:  
12 weeks
• Optional  
before quitting: 
Up to 6 months 
prior to quit date 
with smoking 
reduction
OTC or 
prescription:
 
 
 
• Generic
• Nicoderm CQ
• Nicotrol
Bupropion  
SR 150
Package insert: 
http://bit.ly/ 
1T6NFbM
Steady-state, 
long-acting, 
non-nicotine 
pill; nicotine 
antagonist
Not for use if you:
 
 
 
 
• Use monoamine 
oxidase 
inhibitors 
(MAOIs)
• Use other forms 
of bupropion 
• Have a history  
of seizures
• Have a history of 
eating disorders
 
 
• Insomnia
• Dry mouth
 
 
• Days 1–3: 150 
mg every 
morning
• Days 4–end:  
150 mg  
twice daily
 
 
• Start 1–2 weeks 
before quit date
• Use for  
2–6 months
Prescription only:
 
 
 
• Generic
• Zyban
• Wellbutrin SR
Varenicline
Package insert: 
http://bit.ly/1q9f3rS
Long-acting, 
steady-state 
non-nicotine 
pill; nicotine 
antagonist and 
agonist
Use with caution  
if you:
 
 
 
• Have renal 
impairment
• Have serious 
psychiatric 
illness
• Are undergoing 
dialysis
 
 
 
• Nausea
• Insomnia
• Abnormal 
dreams
 
 
 
• Days 1–3: 0.5 mg 
every morning
• Days 4–7:  
0.5 mg twice 
daily
• Day 8–end:  
1 mg twice daily
 
 
• Start 1 week 
before quit date
• Use for  
3–6 months
Prescription only: 
Chantix
Combinations
 
 
 
• Patch plus 
bupropion
• Patch plus gum
• Patch plus 
lozenge or 
inhaler
 
 
• Only patch plus 
bupropion is 
FDA-approved.
• Follow 
instructions 
for individual 
medications.
See individual 
medications 
above.
See above. See above. See above.
* Excludes pregnant smokers, adolescents, smokers of five or fewer cigarettes per day, and smokeless tobacco users. Insufficient evidence exists to support tobacco 
cessation medication use for these populations.7
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Resources
Improve Delivery System Design 
ZZ Systems Change: Treating Tobacco  
Use and Dependence:  
http://1.usa.gov/1Ty5SZZ 
ZZ A Practical Guide to Working with Health-
Care Systems on Tobacco-Use Treatment: 
http://1.usa.gov/1rLah54
ZZ Healthcare Provider Reminder Systems, 
Provider Education, and Patient Education: 
Working with Healthcare Delivery Systems 
to Improve the Delivery of Tobacco-Use 
Treatment to Patients—An Action Guide:  
http://bit.ly/1q9go20
Increase Evidence-Based Tobacco Cessation 
Brief Interventions 
Practice Resources
ZZ U.S. Public Health Service Clinical  
Practice Guideline:  
http://1.usa.gov/1q9gC9d
ZZ How to Implement the U.S. Public Health 
Service Clinical Practice Guideline:  
http://bit.ly/1SYWemN
ZZ Smoking Cessation in Your Practice:  
http://bit.ly/1XhgMJ3
ZZ Guide to Clinical Preventive Services,  
2014: Tobacco Use in Adults:  
http://1.usa.gov/1WkK4aY
ZZ Clinician resources from the Centers  
for Disease Control and Prevention’s  
Tips From Former Smokers campaign:  
http://1.usa.gov/1rD0AG5
Patient Resources
ZZ 800-QUIT-NOW (800-784-8669)—Free phone 
tobacco cessation quitline, available nationwide
ZZ Tips From Former Smokers:  
http://1.usa.gov/KMtzR3
ZZ Tobacco cessation resources:  
http://1.usa.gov/N7clMw
ZZ SmokefreeTXT—Text message encouragement, 
advice, and tips to help smokers quit:  
http://1.usa.gov/1T7dq8D
ZZ Tobacco cessation resources for women: 
http://1.usa.gov/1WVHCWW
ZZ Tobacco cessation resources for teens: 
http://1.usa.gov/1s7LhFY
ZZ Tobacco cessation resources for veterans: 
http://1.usa.gov/1Okp5wx
ZZ Spanish-language tobacco cessation resources: 
http://1.usa.gov/23BWFoJ
ZZ Smoking Cigarettes: How Do I Quit?:  
http://bit.ly/1UN2mjv
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